INSTIL BIO INC (TIL) Stock Price, Quote, News and Overview
NASDAQ:TIL - Nasdaq - US45783C2008 - Common Stock - Currency: USD
TIL Quote, Performance and Key Statistics
NASDAQ:TIL (6/23/2025, 11:24:24 AM)
29.4
+1.7 (+6.14%)
The current stock price of TIL is 29.4 USD. In the past month the price increased by 70.78%. In the past year, price increased by 168.15%.
TIL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.87 | 324.16B | ||
| AMGN | AMGEN INC | 13.75 | 153.54B | ||
| GILD | GILEAD SCIENCES INC | 13.71 | 131.96B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.54 | 55.21B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.51B | ||
| ARGX | ARGENX SE - ADR | 93.77 | 32.92B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.54 | 27.66B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.79B | ||
| NTRA | NATERA INC | N/A | 23.62B | ||
| INSM | INSMED INC | N/A | 19.02B | ||
| BIIB | BIOGEN INC | 7.9 | 18.32B |
Related stock screener links
About TIL
Company Profile
Instil Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company is headquartered in Dallas, Texas and currently employs 14 full-time employees. The company went IPO on 2021-03-19. The firm seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. The Company’s subsidiary, Axion Bio, Inc., in-licensed certain bispecific antibodies, including AXN-2510/IMM2510 and AXN-27M/IMM27M, a monoclonal antibody targeting cytotoxic T-lymphocyte associated antigen 4, or CTLA-4. AXN-2510/IMM2510, the lead in-licensed product candidate, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumor cancers. AXN-27M/IMM27M is an antibody-dependent cellular cytotoxicity-enhanced monoclonal antibody targeting CTLA-4, which has been designed to promote intratumoral regulatory T cell depletion to enhance the efficacy and reduce the toxicity associated with first-generation anti-CTLA-4 antibodies.
Company Info
INSTIL BIO INC
3963 Maple Avenue, Suite 350
Dallas TEXAS 75219 US
CEO: Bronson Crouch
Employees: 49
Phone: 19724993350
INSTIL BIO INC / TIL FAQ
What is the stock price of INSTIL BIO INC today?
The current stock price of TIL is 29.4 USD. The price increased by 6.14% in the last trading session.
What is the ticker symbol for INSTIL BIO INC stock?
The exchange symbol of INSTIL BIO INC is TIL and it is listed on the Nasdaq exchange.
On which exchange is TIL stock listed?
TIL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for INSTIL BIO INC stock?
8 analysts have analysed TIL and the average price target is 121.04 USD. This implies a price increase of 311.7% is expected in the next year compared to the current price of 29.4. Check the INSTIL BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is INSTIL BIO INC worth?
INSTIL BIO INC (TIL) has a market capitalization of 192.86M USD. This makes TIL a Micro Cap stock.
How many employees does INSTIL BIO INC have?
INSTIL BIO INC (TIL) currently has 49 employees.
What are the support and resistance levels for INSTIL BIO INC (TIL) stock?
INSTIL BIO INC (TIL) has a support level at 27.69 and a resistance level at 36.31. Check the full technical report for a detailed analysis of TIL support and resistance levels.
Should I buy INSTIL BIO INC (TIL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TIL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TIL, evaluating the profitability, health, valuation and growth aspects
- INSTIL BIO INC (TIL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- INSTIL BIO INC (TIL) Sales and EPS estimates to see what analysts future expectations are.
- INSTIL BIO INC (TIL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- INSTIL BIO INC (TIL) Insider and Institutional Ownership to learn about the owners and their transactions.
- INSTIL BIO INC (TIL) Stock Chart to make your own analysis
- INSTIL BIO INC (TIL) Latest news and press-releases to stay up to date.
Does INSTIL BIO INC (TIL) stock pay dividends?
TIL does not pay a dividend.
When does INSTIL BIO INC (TIL) report earnings?
INSTIL BIO INC (TIL) will report earnings on 2025-08-11, before the market open.
What is the Price/Earnings (PE) ratio of INSTIL BIO INC (TIL)?
INSTIL BIO INC (TIL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.97).
What is the Short Interest ratio of INSTIL BIO INC (TIL) stock?
The outstanding short interest for INSTIL BIO INC (TIL) is 10.13% of its float. Check the ownership tab for more information on the TIL short interest.
TIL Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to TIL. When comparing the yearly performance of all stocks, TIL is one of the better performing stocks in the market, outperforming 97.96% of all stocks.
TIL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TIL. The financial health of TIL is average, but there are quite some concerns on its profitability.
TIL Financial Highlights
Over the last trailing twelve months TIL reported a non-GAAP Earnings per Share(EPS) of -11.97. The EPS increased by 36.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.9% | ||
| ROE | -53.91% | ||
| Debt/Equity | 0.58 |
TIL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to TIL. The Buy consensus is the average rating of analysts ratings from 8 analysts.